<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01794780</url>
  </required_header>
  <id_info>
    <org_study_id>CQAB149BCN01</org_study_id>
    <nct_id>NCT01794780</nct_id>
  </id_info>
  <brief_title>A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator</brief_title>
  <official_title>A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-center study is designed to describe natural history of disease, treatment and
      health care products in physician-diagnosed COPD patients who require adding daily
      maintenance therapy in real world.

      The study planned to enroll 550 patients in Indacaterol group and 9450 patients in non-
      Indacaterol group, a total of 10,000 patients. Enrollment was stopped at 2253 patients due to
      low recruitment in indacaterol group. Finally a total of 2229 patients were analyzed in full
      analysis set.

      A total of 2253 patients entered into the database, of which 24 patients were exclude during
      the data review meetings, because they did not met the inclusion/exclusion criteria. Hence a
      total of 2229 patients enrolled successfully.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 5, 2013</start_date>
  <completion_date type="Actual">May 25, 2015</completion_date>
  <primary_completion_date type="Actual">May 25, 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Baseline,3 months</time_frame>
    <description>Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. A positive change from baseline in FEV1 indicates improvement in lung function. Pulmonary function tests were performed at study visits including FEV1, and Force Vital Capacity (FVC). These were performed 30 minutes before treatment and not more than 2 hours in advance after stopping the Long-acting bronchodilators eight hours before visits. In order to reduce the variation between each test, the same instrument was used in the whole research process if condition allowed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Baseline,12 months</time_frame>
    <description>Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. A positive change from baseline in FEV1 indicates improvement in lung function. Pulmonary function tests were performed at study visits including FEV1, and Force Vital Capacity (FVC). These were performed 30 minutes before treatment and not more than 2 hours in advance after stopping the long-acting bronchodilators eight hours before visits. In order to reduce the variation between each test, the same instrument was used in the whole research process if condition allowed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COPD Exacerbation</measure>
    <time_frame>Baseline,12 months</time_frame>
    <description>Number of COPD exacerbations evaluated over 12 months. COPD exacerbation is defined as a new onset or worsening of at least 1 respiratory major symptoms (e.g. dyspnea, cough, sputum volume or sputum purulence) for at least 3 consecutive days, which results in recorded treatment change (antibiotics/steroids/oxygen therapy) OR recorded COPD related hospitalization/Emergency visit. COPD exacerbation is not considered as adverse event, and should only be recorded in COPD e-CRF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Health Status Questionnaire MMRC</measure>
    <time_frame>Baseline,3,6,9,12 months</time_frame>
    <description>The mMRC scale is scored from 0 (less severe) to 4 (severe). 0 Not troubled with breathlessness except with strenuous exercise; 1 Troubled by shortness of breath when hurrying on the level or walking up a slight hill; 2 Walks slower than people of the same age on the level because of breathlessness or has to stop for breath when walking at own pace on the level; 3 Stops for breath after walking about 100 yards or after a few minutes on the level; 4 Too breathless to leave the house or breathless when dressing or undressing. The modified Medical Research Council (mMRC) Dyspnea Scale , is a five-item instrument (part of the Borg scale) to assess a patient's degree of breathlessness in relation to physical activity. Participants will be required to read a brief description of an activity and then select a statement that best describes their experience with dyspnea at Visit 101. The mMRC was assessed by the investigators at the scheduled visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Questionnaire COPD Assessment Test (CAT) Score</measure>
    <time_frame>Baseline,3,6,9,12 months</time_frame>
    <description>The COPD assessment test (CAT) is a short instrument scale used to quantify the symptom burden of COPD and will be used to assess the health status of patients in this study. It consists of eight items, each presented as a semantic 6-point differential scale, providing a total score out of 40. A higher score indicates a worse health status. Scores of 0 - 10, 11 - 20, 21 - 30 and 31 - 40 represent a mild, moderate, severe or very severe clinical impact of COPD upon the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Questionnaire Transition Dyspnea Index (TDI) Score</measure>
    <time_frame>Baseline,3,6,9,12 months</time_frame>
    <description>Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline. BDI/TDI was used to assess dyspnea from several aspects, caused by daily activities. These were evaluated by the investigators in the study at the scheduled study visits. The indices were to be evaluated by the same investigator.as far as possible.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">2229</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Indacaterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LABA: Indacaterol, once a day, 150μg each time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium Bromide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LAMA: Tiotropium Bromide, once a day, 18 μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salmeterol/Fluticasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LABA/ICS: Salmeterol/Fluticasone, twice a day, 50/250 μg, 50/500 μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide/ formoterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budesonide/formoterol, twice daily, two suction each time, 160/4.5 μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Indacaterol +Tiotropium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Indacaterol, once a day, 150μg each time +Tiotropium Bromide, once a day, 18 μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LABA/ICS (Or budesonide/ formoterol)+ Tiotropium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Salmeterol / fluticasone Or budesonide / formoterol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral theophylline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Other treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>non-long-acting bronchodilators for COPD treatment, such treatments were classified as &quot;other treatments&quot;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LABA based treatment: indacaterol</intervention_name>
    <description>LABA based treatment: indacaterol</description>
    <arm_group_label>Indacaterol</arm_group_label>
    <arm_group_label>Indacaterol +Tiotropium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAMA based treatment: tiotropium</intervention_name>
    <description>LAMA based treatment: tiotropium</description>
    <arm_group_label>Indacaterol +Tiotropium</arm_group_label>
    <arm_group_label>LABA/ICS (Or budesonide/ formoterol)+ Tiotropium</arm_group_label>
    <arm_group_label>Tiotropium Bromide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LABA/ICS based treatment: salmeterol/fluticasone</intervention_name>
    <description>LABA/ICS based treatment: salmeterol/fluticasone</description>
    <arm_group_label>LABA/ICS (Or budesonide/ formoterol)+ Tiotropium</arm_group_label>
    <arm_group_label>Salmeterol/Fluticasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LABA/ICS based treatment: budesonide/formoterol</intervention_name>
    <description>LABA/ICS based treatment: budesonide/formoterol</description>
    <arm_group_label>Budesonide/ formoterol</arm_group_label>
    <arm_group_label>LABA/ICS (Or budesonide/ formoterol)+ Tiotropium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>theophylline based treatment</intervention_name>
    <description>theophylline based treatment</description>
    <arm_group_label>Oral theophylline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Other treatment</intervention_name>
    <description>non-long-acting bronchodilators for COPD treatment, such treatments were classified as &quot;other treatments&quot;</description>
    <arm_group_label>Other treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to provide informed consent

          -  Physician-diagnosis of COPD

          -  COPD patients requiring long-acting bronchodilator treatment

          -  Patients with spirometry available at baseline

        Exclusion Criteria:

          -  Patients who have a diagnosis of asthma.

          -  Patients who had been hospitalized for a COPD exacerbation in the 4 weeks prior to
             Visit 1.

          -  Current clinical diagnosis of other chronic respiratory illnesses

          -  Concurrent participation in a clinical trial or use of an investigational drug.

          -  Active malignancy or history of malignancy of any organ system

          -  Pregnant or nursing (lactating) women

          -  Women of child-bearing potential with no contraception Other protocol-defined
             inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>February 15, 2013</study_first_submitted>
  <study_first_submitted_qc>February 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2013</study_first_posted>
  <results_first_submitted>June 1, 2017</results_first_submitted>
  <results_first_submitted_qc>August 27, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 26, 2019</results_first_posted>
  <last_update_submitted>August 27, 2019</last_update_submitted>
  <last_update_submitted_qc>August 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Chronic obstructive pulmonary disease (COPD),</keyword>
  <keyword>Chronic obstructive lung disease (COLD),</keyword>
  <keyword>Chronic obstructive airway disease (COAD),</keyword>
  <keyword>Cronchitis,</keyword>
  <keyword>Emphysema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Theophylline</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 2253 patients entered into the database, of which 24 patients were exclude during the data review meetings, because they did not met the inclusion/exclusion criteria. Hence a total of 2229 patients enrolled successfully.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Indacaterol</title>
          <description>LABA: Indacaterol, once a day, 150μg each time</description>
        </group>
        <group group_id="P2">
          <title>Tiotropium Bromide</title>
          <description>LAMA: Tiotropium Bromide, once a day, 18 μg</description>
        </group>
        <group group_id="P3">
          <title>Salmeterol/Fluticasone</title>
          <description>LABA/ICS: Salmeterol/Fluticasone, twice a day, 50/250 μg, 50/500 μg</description>
        </group>
        <group group_id="P4">
          <title>Budesonide/ Formoterol</title>
          <description>Budesonide/formoterol, twice daily, two suction each time, 160/4.5 μg</description>
        </group>
        <group group_id="P5">
          <title>Indacaterol +Tiotropium</title>
          <description>Indacaterol, once a day, 150μg each time +Tiotropium Bromide, once a day, 18 μg</description>
        </group>
        <group group_id="P6">
          <title>LABA/ICS (Or Budesonide/ Formoterol)+ Tiotropium</title>
          <description>Salmeterol / fluticasone Or budesonide / formoterol</description>
        </group>
        <group group_id="P7">
          <title>Oral Theophylline</title>
          <description>Oral theophylline</description>
        </group>
        <group group_id="P8">
          <title>Other Treatment</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="276"/>
                <participants group_id="P3" count="813"/>
                <participants group_id="P4" count="283"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="632"/>
                <participants group_id="P7" count="154"/>
                <participants group_id="P8" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="180"/>
                <participants group_id="P3" count="571"/>
                <participants group_id="P4" count="200"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="452"/>
                <participants group_id="P7" count="112"/>
                <participants group_id="P8" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="96"/>
                <participants group_id="P3" count="242"/>
                <participants group_id="P4" count="83"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="180"/>
                <participants group_id="P7" count="42"/>
                <participants group_id="P8" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="165"/>
                <participants group_id="P4" count="53"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="99"/>
                <participants group_id="P7" count="30"/>
                <participants group_id="P8" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew informed consent</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="48"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="24"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Indacaterol</title>
          <description>LABA: Indacaterol, once a day, 150μg each time</description>
        </group>
        <group group_id="B2">
          <title>Tiotropium Bromide</title>
          <description>LAMA: Tiotropium Bromide, once a day, 18 μg</description>
        </group>
        <group group_id="B3">
          <title>Salmeterol/Fluticasone</title>
          <description>LABA/ICS: Salmeterol/Fluticasone, twice a day, 50/250 μg, 50/500 μg</description>
        </group>
        <group group_id="B4">
          <title>Budesonide/ Formoterol</title>
          <description>Budesonide/formoterol, twice daily, two suction each time, 160/4.5 μg</description>
        </group>
        <group group_id="B5">
          <title>Indacaterol +Tiotropium</title>
          <description>Indacaterol, once a day, 150μg each time +Tiotropium Bromide, once a day, 18 μg</description>
        </group>
        <group group_id="B6">
          <title>LABA/ICS (Or Budesonide/ Formoterol)+ Tiotropium</title>
          <description>Salmeterol / fluticasone Or budesonide / formoterol</description>
        </group>
        <group group_id="B7">
          <title>Oral Theophylline</title>
          <description>Oral theophylline</description>
        </group>
        <group group_id="B8">
          <title>Other Treatment</title>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="276"/>
            <count group_id="B3" value="813"/>
            <count group_id="B4" value="283"/>
            <count group_id="B5" value="9"/>
            <count group_id="B6" value="632"/>
            <count group_id="B7" value="154"/>
            <count group_id="B8" value="30"/>
            <count group_id="B9" value="2229"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.12" spread="9.238"/>
                    <measurement group_id="B2" value="68.93" spread="9.145"/>
                    <measurement group_id="B3" value="67.00" spread="9.353"/>
                    <measurement group_id="B4" value="67.02" spread="9.858"/>
                    <measurement group_id="B5" value="69.49" spread="8.873"/>
                    <measurement group_id="B6" value="67.74" spread="9.427"/>
                    <measurement group_id="B7" value="67.86" spread="9.652"/>
                    <measurement group_id="B8" value="66.14" spread="10.205"/>
                    <measurement group_id="B9" value="67.50" spread="9.453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="154"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="81"/>
                    <measurement group_id="B7" value="35"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="378"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="224"/>
                    <measurement group_id="B3" value="659"/>
                    <measurement group_id="B4" value="234"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="551"/>
                    <measurement group_id="B7" value="119"/>
                    <measurement group_id="B8" value="25"/>
                    <measurement group_id="B9" value="1851"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. A positive change from baseline in FEV1 indicates improvement in lung function. Pulmonary function tests were performed at study visits including FEV1, and Force Vital Capacity (FVC). These were performed 30 minutes before treatment and not more than 2 hours in advance after stopping the Long-acting bronchodilators eight hours before visits. In order to reduce the variation between each test, the same instrument was used in the whole research process if condition allowed.</description>
        <time_frame>Baseline,3 months</time_frame>
        <population>FAS: Two Arms/Groups were grouped together in the analysis as some of the analysis required to combine the results. Per protocol it was not the intent to compare the results between different standard of care (LABA/ICS). Efficacy data were not collected separately for the &quot;Salmeterol / fluticasone&quot; and &quot;budesonide / formoterol&quot; Arms/Groups,&quot;</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol</title>
            <description>LABA: Indacaterol, once a day, 150μg each time</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>LAMA: Tiotropium Bromide, once a day, 18 μg</description>
          </group>
          <group group_id="O3">
            <title>LABA/ICS</title>
            <description>Salmeterol / fluticasone Or budesonide / formoterol</description>
          </group>
          <group group_id="O4">
            <title>Indacaterol + Tiotropium</title>
            <description>Indacaterol, once a day, 150μg each time +Tiotropium Bromide, once a day, 18 μg</description>
          </group>
          <group group_id="O5">
            <title>LABA/ICS + Tiotropium</title>
            <description>(Salmeterol / fluticasone Or budesonide / formoterol) + tiotropium</description>
          </group>
          <group group_id="O6">
            <title>Oral Theophylline</title>
            <description>Oral theophylline</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. A positive change from baseline in FEV1 indicates improvement in lung function. Pulmonary function tests were performed at study visits including FEV1, and Force Vital Capacity (FVC). These were performed 30 minutes before treatment and not more than 2 hours in advance after stopping the Long-acting bronchodilators eight hours before visits. In order to reduce the variation between each test, the same instrument was used in the whole research process if condition allowed.</description>
          <population>FAS: Two Arms/Groups were grouped together in the analysis as some of the analysis required to combine the results. Per protocol it was not the intent to compare the results between different standard of care (LABA/ICS). Efficacy data were not collected separately for the &quot;Salmeterol / fluticasone&quot; and &quot;budesonide / formoterol&quot; Arms/Groups,&quot;</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="154"/>
                <count group_id="O3" value="702"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="404"/>
                <count group_id="O6" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.042" spread="0.1742"/>
                    <measurement group_id="O2" value="0.006" spread="0.2537"/>
                    <measurement group_id="O3" value="0.033" spread="0.3790"/>
                    <measurement group_id="O4" value="0.022" spread="0.1157"/>
                    <measurement group_id="O5" value="0.011" spread="0.2417"/>
                    <measurement group_id="O6" value="0.012" spread="0.3405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. A positive change from baseline in FEV1 indicates improvement in lung function. Pulmonary function tests were performed at study visits including FEV1, and Force Vital Capacity (FVC). These were performed 30 minutes before treatment and not more than 2 hours in advance after stopping the long-acting bronchodilators eight hours before visits. In order to reduce the variation between each test, the same instrument was used in the whole research process if condition allowed.</description>
        <time_frame>Baseline,12 months</time_frame>
        <population>FAS: Two Arms/Groups were grouped together in the analysis as some of the analysis required to combine the results. Per protocol it was not the intent to compare the results between different standard of care (LABA/ICS). Efficacy data were not collected separately for the &quot;Salmeterol / fluticasone&quot; and &quot;budesonide / formoterol&quot; Arms/Groups,&quot;</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol</title>
            <description>LABA: Indacaterol, once a day, 150μg each time</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide</title>
            <description>LAMA: Tiotropium Bromide, once a day, 18 μg</description>
          </group>
          <group group_id="O3">
            <title>LABA/ICS</title>
            <description>Salmeterol / fluticasone Or budesonide / formoterol</description>
          </group>
          <group group_id="O4">
            <title>Indacaterol +Tiotropium</title>
            <description>Indacaterol, once a day, 150μg each time +Tiotropium Bromide, once a day, 18 μg</description>
          </group>
          <group group_id="O5">
            <title>LABA/ICS + Tiotropium</title>
            <description>(Salmeterol / fluticasone Or budesonide / formoterol) + tiotropium</description>
          </group>
          <group group_id="O6">
            <title>Oral Theophylline</title>
            <description>Oral theophylline</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. A positive change from baseline in FEV1 indicates improvement in lung function. Pulmonary function tests were performed at study visits including FEV1, and Force Vital Capacity (FVC). These were performed 30 minutes before treatment and not more than 2 hours in advance after stopping the long-acting bronchodilators eight hours before visits. In order to reduce the variation between each test, the same instrument was used in the whole research process if condition allowed.</description>
          <population>FAS: Two Arms/Groups were grouped together in the analysis as some of the analysis required to combine the results. Per protocol it was not the intent to compare the results between different standard of care (LABA/ICS). Efficacy data were not collected separately for the &quot;Salmeterol / fluticasone&quot; and &quot;budesonide / formoterol&quot; Arms/Groups,&quot;</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="129"/>
                <count group_id="O3" value="597"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="317"/>
                <count group_id="O6" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.056" spread="0.2137"/>
                    <measurement group_id="O2" value="-0.036" spread="0.2395"/>
                    <measurement group_id="O3" value="0.056" spread="0.4335"/>
                    <measurement group_id="O4" value="0.030" spread="0.0854"/>
                    <measurement group_id="O5" value="-0.028" spread="0.2258"/>
                    <measurement group_id="O6" value="0.046" spread="0.3654"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>COPD Exacerbation</title>
        <description>Number of COPD exacerbations evaluated over 12 months. COPD exacerbation is defined as a new onset or worsening of at least 1 respiratory major symptoms (e.g. dyspnea, cough, sputum volume or sputum purulence) for at least 3 consecutive days, which results in recorded treatment change (antibiotics/steroids/oxygen therapy) OR recorded COPD related hospitalization/Emergency visit. COPD exacerbation is not considered as adverse event, and should only be recorded in COPD e-CRF.</description>
        <time_frame>Baseline,12 months</time_frame>
        <population>FAS: Two Arms/Groups were grouped together in the analysis as some of the analysis required to combine the results. Per protocol it was not the intent to compare the results between different standard of care (LABA/ICS)</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol</title>
            <description>LABA: Indacaterol, once a day, 150μg each time</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide</title>
            <description>LAMA: Tiotropium Bromide, once a day, 18 μg</description>
          </group>
          <group group_id="O3">
            <title>Salmeterol/Fluticasone</title>
            <description>LABA/ICS: Salmeterol/Fluticasone, twice a day, 50/250 μg, 50/500 μg</description>
          </group>
          <group group_id="O4">
            <title>Budesonide/ Formoterol</title>
            <description>Budesonide/formoterol, twice daily, two suction each time, 160/4.5 μg</description>
          </group>
          <group group_id="O5">
            <title>LABA/ICS</title>
            <description>Salmeterol / fluticasone Or budesonide / formoterol</description>
          </group>
          <group group_id="O6">
            <title>Indacaterol +Tiotropium</title>
            <description>Indacaterol, once a day, 150μg each time +Tiotropium Bromide, once a day, 18 μg</description>
          </group>
          <group group_id="O7">
            <title>LABA/ICS + Tiotropium</title>
            <description>(Salmeterol / fluticasone Or budesonide / formoterol) + tiotropium</description>
          </group>
          <group group_id="O8">
            <title>Oral Theophylline</title>
            <description>Oral theophylline</description>
          </group>
        </group_list>
        <measure>
          <title>COPD Exacerbation</title>
          <description>Number of COPD exacerbations evaluated over 12 months. COPD exacerbation is defined as a new onset or worsening of at least 1 respiratory major symptoms (e.g. dyspnea, cough, sputum volume or sputum purulence) for at least 3 consecutive days, which results in recorded treatment change (antibiotics/steroids/oxygen therapy) OR recorded COPD related hospitalization/Emergency visit. COPD exacerbation is not considered as adverse event, and should only be recorded in COPD e-CRF.</description>
          <population>FAS: Two Arms/Groups were grouped together in the analysis as some of the analysis required to combine the results. Per protocol it was not the intent to compare the results between different standard of care (LABA/ICS)</population>
          <units>COPD Exacerbations/year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="276"/>
                <count group_id="O3" value="813"/>
                <count group_id="O4" value="283"/>
                <count group_id="O5" value="1096"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="632"/>
                <count group_id="O8" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="3.53"/>
                    <measurement group_id="O2" value="0.5" spread="1.89"/>
                    <measurement group_id="O3" value="1.1" spread="7.74"/>
                    <measurement group_id="O4" value="0.4" spread="1.89"/>
                    <measurement group_id="O5" value="0.9" spread="6.72"/>
                    <measurement group_id="O6" value="4.1" spread="5.46"/>
                    <measurement group_id="O7" value="0.8" spread="3.47"/>
                    <measurement group_id="O8" value="1.0" spread="3.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Health Status Questionnaire MMRC</title>
        <description>The mMRC scale is scored from 0 (less severe) to 4 (severe). 0 Not troubled with breathlessness except with strenuous exercise; 1 Troubled by shortness of breath when hurrying on the level or walking up a slight hill; 2 Walks slower than people of the same age on the level because of breathlessness or has to stop for breath when walking at own pace on the level; 3 Stops for breath after walking about 100 yards or after a few minutes on the level; 4 Too breathless to leave the house or breathless when dressing or undressing. The modified Medical Research Council (mMRC) Dyspnea Scale , is a five-item instrument (part of the Borg scale) to assess a patient's degree of breathlessness in relation to physical activity. Participants will be required to read a brief description of an activity and then select a statement that best describes their experience with dyspnea at Visit 101. The mMRC was assessed by the investigators at the scheduled visits.</description>
        <time_frame>Baseline,3,6,9,12 months</time_frame>
        <population>FAS: Two Arms/Groups were grouped together in the analysis as some of the analysis required to combine the results. Per protocol it was not the intent to compare the results between different standard of care (LABA/ICS).Efficacy data were not collected separately for the &quot;Salmeterol / fluticasone&quot; and &quot;budesonide / formoterol&quot; Arms/Groups,&quot;</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol</title>
            <description>LABA: Indacaterol, once a day, 150μg each time</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide</title>
            <description>LAMA: Tiotropium Bromide, once a day, 18 μg</description>
          </group>
          <group group_id="O3">
            <title>LABA/ICS</title>
            <description>Salmeterol / fluticasone Or budesonide / formoterol</description>
          </group>
          <group group_id="O4">
            <title>Indacaterol +Tiotropium</title>
            <description>Indacaterol, once a day, 150μg each time +Tiotropium Bromide, once a day, 18 μg</description>
          </group>
          <group group_id="O5">
            <title>LABA/ICS + Tiotropium</title>
            <description>(Salmeterol / fluticasone Or budesonide / formoterol) + tiotropium</description>
          </group>
          <group group_id="O6">
            <title>Oral Theophylline</title>
            <description>Oral theophylline</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Health Status Questionnaire MMRC</title>
          <description>The mMRC scale is scored from 0 (less severe) to 4 (severe). 0 Not troubled with breathlessness except with strenuous exercise; 1 Troubled by shortness of breath when hurrying on the level or walking up a slight hill; 2 Walks slower than people of the same age on the level because of breathlessness or has to stop for breath when walking at own pace on the level; 3 Stops for breath after walking about 100 yards or after a few minutes on the level; 4 Too breathless to leave the house or breathless when dressing or undressing. The modified Medical Research Council (mMRC) Dyspnea Scale , is a five-item instrument (part of the Borg scale) to assess a patient's degree of breathlessness in relation to physical activity. Participants will be required to read a brief description of an activity and then select a statement that best describes their experience with dyspnea at Visit 101. The mMRC was assessed by the investigators at the scheduled visits.</description>
          <population>FAS: Two Arms/Groups were grouped together in the analysis as some of the analysis required to combine the results. Per protocol it was not the intent to compare the results between different standard of care (LABA/ICS).Efficacy data were not collected separately for the &quot;Salmeterol / fluticasone&quot; and &quot;budesonide / formoterol&quot; Arms/Groups,&quot;</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="276"/>
                <count group_id="O3" value="1096"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="632"/>
                <count group_id="O6" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline scale item 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="276"/>
                    <count group_id="O3" value="1096"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="632"/>
                    <count group_id="O6" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="161"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="63"/>
                    <measurement group_id="O6" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline scale item 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="276"/>
                    <count group_id="O3" value="1096"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="632"/>
                    <count group_id="O6" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="114"/>
                    <measurement group_id="O3" value="435"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="226"/>
                    <measurement group_id="O6" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline scale item 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="276"/>
                    <count group_id="O3" value="1096"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="632"/>
                    <count group_id="O6" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="327"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="211"/>
                    <measurement group_id="O6" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline scale item 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="276"/>
                    <count group_id="O3" value="1096"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="632"/>
                    <count group_id="O6" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="154"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="110"/>
                    <measurement group_id="O6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline scale item 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="276"/>
                    <count group_id="O3" value="1096"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="632"/>
                    <count group_id="O6" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 month Scale item 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="167"/>
                    <count group_id="O3" value="741"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="411"/>
                    <count group_id="O6" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="101"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="54"/>
                    <measurement group_id="O6" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 month Scale item 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="167"/>
                    <count group_id="O3" value="741"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="411"/>
                    <count group_id="O6" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="364"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="157"/>
                    <measurement group_id="O6" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 month Scale item 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="167"/>
                    <count group_id="O3" value="741"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="411"/>
                    <count group_id="O6" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="203"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="133"/>
                    <measurement group_id="O6" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 month Scale item 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="167"/>
                    <count group_id="O3" value="741"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="411"/>
                    <count group_id="O6" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="67"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="58"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 month Scale item 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="167"/>
                    <count group_id="O3" value="741"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="411"/>
                    <count group_id="O6" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 month Scale item 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="141"/>
                    <count group_id="O3" value="583"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="346"/>
                    <count group_id="O6" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="96"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="37"/>
                    <measurement group_id="O6" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 month Scale item 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="141"/>
                    <count group_id="O3" value="583"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="346"/>
                    <count group_id="O6" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="290"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="149"/>
                    <measurement group_id="O6" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 month Scale item 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="141"/>
                    <count group_id="O3" value="583"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="346"/>
                    <count group_id="O6" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="138"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="105"/>
                    <measurement group_id="O6" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 month Scale item 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="141"/>
                    <count group_id="O3" value="583"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="346"/>
                    <count group_id="O6" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="44"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 month Scale item 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="141"/>
                    <count group_id="O3" value="583"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="346"/>
                    <count group_id="O6" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 month Scale item 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="121"/>
                    <count group_id="O3" value="549"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="321"/>
                    <count group_id="O6" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="116"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="45"/>
                    <measurement group_id="O6" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 month Scale item 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="121"/>
                    <count group_id="O3" value="549"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="321"/>
                    <count group_id="O6" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="256"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="127"/>
                    <measurement group_id="O6" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 month Scale item 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="121"/>
                    <count group_id="O3" value="549"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="321"/>
                    <count group_id="O6" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="131"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="99"/>
                    <measurement group_id="O6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 month Scale item 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="121"/>
                    <count group_id="O3" value="549"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="321"/>
                    <count group_id="O6" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="41"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 month Scale item 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="121"/>
                    <count group_id="O3" value="549"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="321"/>
                    <count group_id="O6" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 month Scale item 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="602"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="328"/>
                    <count group_id="O6" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="150"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="47"/>
                    <measurement group_id="O6" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 month Scale item 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="602"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="328"/>
                    <count group_id="O6" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="275"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="138"/>
                    <measurement group_id="O6" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 month Scale item 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="602"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="328"/>
                    <count group_id="O6" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="127"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="102"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 month Scale item 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="602"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="328"/>
                    <count group_id="O6" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="32"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 month Scale item 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="602"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="328"/>
                    <count group_id="O6" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Questionnaire COPD Assessment Test (CAT) Score</title>
        <description>The COPD assessment test (CAT) is a short instrument scale used to quantify the symptom burden of COPD and will be used to assess the health status of patients in this study. It consists of eight items, each presented as a semantic 6-point differential scale, providing a total score out of 40. A higher score indicates a worse health status. Scores of 0 - 10, 11 - 20, 21 - 30 and 31 - 40 represent a mild, moderate, severe or very severe clinical impact of COPD upon the patient.</description>
        <time_frame>Baseline,3,6,9,12 months</time_frame>
        <population>FAS: Two Arms/Groups were grouped together in the analysis as some of the analysis required to combine the results. Per protocol it was not the intent to compare the results between different standard of care (LABA/ICS). Efficacy data were not collected separately for the &quot;Salmeterol / fluticasone&quot; and &quot;budesonide / formoterol&quot; Arms/Groups,&quot;</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol</title>
            <description>LABA: Indacaterol, once a day, 150μg each time</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide</title>
            <description>LAMA: Tiotropium Bromide, once a day, 18 μg</description>
          </group>
          <group group_id="O3">
            <title>LABA/ICS</title>
            <description>Salmeterol / fluticasone Or budesonide / formoterol</description>
          </group>
          <group group_id="O4">
            <title>Indacaterol +Tiotropium</title>
            <description>Indacaterol, once a day, 150μg each time +Tiotropium Bromide, once a day, 18 μg</description>
          </group>
          <group group_id="O5">
            <title>LABA/ICS + Tiotropium</title>
            <description>(Salmeterol / fluticasone Or budesonide / formoterol) + tiotropium</description>
          </group>
          <group group_id="O6">
            <title>Oral Theophylline</title>
            <description>Oral theophylline</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Questionnaire COPD Assessment Test (CAT) Score</title>
          <description>The COPD assessment test (CAT) is a short instrument scale used to quantify the symptom burden of COPD and will be used to assess the health status of patients in this study. It consists of eight items, each presented as a semantic 6-point differential scale, providing a total score out of 40. A higher score indicates a worse health status. Scores of 0 - 10, 11 - 20, 21 - 30 and 31 - 40 represent a mild, moderate, severe or very severe clinical impact of COPD upon the patient.</description>
          <population>FAS: Two Arms/Groups were grouped together in the analysis as some of the analysis required to combine the results. Per protocol it was not the intent to compare the results between different standard of care (LABA/ICS). Efficacy data were not collected separately for the &quot;Salmeterol / fluticasone&quot; and &quot;budesonide / formoterol&quot; Arms/Groups,&quot;</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="276"/>
                <count group_id="O3" value="1096"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="632"/>
                <count group_id="O6" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="167"/>
                    <count group_id="O3" value="741"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="411"/>
                    <count group_id="O6" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="5.12"/>
                    <measurement group_id="O2" value="-2.1" spread="5.58"/>
                    <measurement group_id="O3" value="-2.3" spread="5.68"/>
                    <measurement group_id="O4" value="-1.9" spread="2.67"/>
                    <measurement group_id="O5" value="-1.8" spread="5.96"/>
                    <measurement group_id="O6" value="-1.8" spread="4.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="140"/>
                    <count group_id="O3" value="582"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="346"/>
                    <count group_id="O6" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="5.80"/>
                    <measurement group_id="O2" value="-2.7" spread="5.78"/>
                    <measurement group_id="O3" value="-2.7" spread="5.89"/>
                    <measurement group_id="O4" value="-2.7" spread="5.01"/>
                    <measurement group_id="O5" value="-2.2" spread="6.46"/>
                    <measurement group_id="O6" value="-2.5" spread="5.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 Month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="121"/>
                    <count group_id="O3" value="549"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="321"/>
                    <count group_id="O6" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="5.27"/>
                    <measurement group_id="O2" value="-3.1" spread="6.02"/>
                    <measurement group_id="O3" value="-3.5" spread="6.66"/>
                    <measurement group_id="O4" value="-9.0" spread="2.65"/>
                    <measurement group_id="O5" value="-3.1" spread="6.49"/>
                    <measurement group_id="O6" value="-3.1" spread="6.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="603"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="328"/>
                    <count group_id="O6" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.1" spread="3.98"/>
                    <measurement group_id="O2" value="-2.6" spread="6.74"/>
                    <measurement group_id="O3" value="-4.1" spread="7.09"/>
                    <measurement group_id="O4" value="-7.7" spread="0.58"/>
                    <measurement group_id="O5" value="-3.7" spread="6.45"/>
                    <measurement group_id="O6" value="-2.4" spread="7.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Questionnaire Transition Dyspnea Index (TDI) Score</title>
        <description>Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline. BDI/TDI was used to assess dyspnea from several aspects, caused by daily activities. These were evaluated by the investigators in the study at the scheduled study visits. The indices were to be evaluated by the same investigator.as far as possible.</description>
        <time_frame>Baseline,3,6,9,12 months</time_frame>
        <population>FAS: Two Arms/Groups were grouped together in the analysis as some of the analysis required to combine the results. Per protocol it was not the intent to compare the results between different standard of care (LABA/ICS). Efficacy data were not collected separately for the &quot;Salmeterol / fluticasone&quot; and &quot;budesonide / formoterol&quot; Arms/Groups,&quot;</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol</title>
            <description>LABA: Indacaterol, once a day, 150μg each time</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide</title>
            <description>LAMA: Tiotropium Bromide, once a day, 18 μg</description>
          </group>
          <group group_id="O3">
            <title>LABA/ICS</title>
            <description>Salmeterol / fluticasone Or budesonide / formoterol</description>
          </group>
          <group group_id="O4">
            <title>Indacaterol +Tiotropium</title>
            <description>Indacaterol, once a day, 150μg each time +Tiotropium Bromide, once a day, 18 μg</description>
          </group>
          <group group_id="O5">
            <title>LABA/ICS + Tiotropium</title>
            <description>Salmeterol / fluticasone Or budesonide / formoterol) + tiotropium</description>
          </group>
          <group group_id="O6">
            <title>Oral Theophylline</title>
            <description>Oral theophylline</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Questionnaire Transition Dyspnea Index (TDI) Score</title>
          <description>Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline. BDI/TDI was used to assess dyspnea from several aspects, caused by daily activities. These were evaluated by the investigators in the study at the scheduled study visits. The indices were to be evaluated by the same investigator.as far as possible.</description>
          <population>FAS: Two Arms/Groups were grouped together in the analysis as some of the analysis required to combine the results. Per protocol it was not the intent to compare the results between different standard of care (LABA/ICS). Efficacy data were not collected separately for the &quot;Salmeterol / fluticasone&quot; and &quot;budesonide / formoterol&quot; Arms/Groups,&quot;</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="276"/>
                <count group_id="O3" value="1096"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="632"/>
                <count group_id="O6" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="271"/>
                    <count group_id="O3" value="1078"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="624"/>
                    <count group_id="O6" value="150"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="2.27"/>
                    <measurement group_id="O2" value="6.6" spread="2.66"/>
                    <measurement group_id="O3" value="6.7" spread="2.66"/>
                    <measurement group_id="O4" value="5.4" spread="2.24"/>
                    <measurement group_id="O5" value="6.2" spread="2.60"/>
                    <measurement group_id="O6" value="7.1" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="167"/>
                    <count group_id="O3" value="740"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="411"/>
                    <count group_id="O6" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="2.61"/>
                    <measurement group_id="O2" value="1.2" spread="2.43"/>
                    <measurement group_id="O3" value="1.3" spread="2.59"/>
                    <measurement group_id="O4" value="0.4" spread="2.07"/>
                    <measurement group_id="O5" value="1.1" spread="2.50"/>
                    <measurement group_id="O6" value="0.9" spread="2.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="141"/>
                    <count group_id="O3" value="582"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="345"/>
                    <count group_id="O6" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="2.45"/>
                    <measurement group_id="O2" value="1.0" spread="2.67"/>
                    <measurement group_id="O3" value="1.4" spread="2.59"/>
                    <measurement group_id="O4" value="-0.5" spread="2.26"/>
                    <measurement group_id="O5" value="0.9" spread="2.36"/>
                    <measurement group_id="O6" value="1.2" spread="2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 Month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="549"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="320"/>
                    <count group_id="O6" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.23"/>
                    <measurement group_id="O2" value="0.9" spread="2.48"/>
                    <measurement group_id="O3" value="1.6" spread="2.78"/>
                    <measurement group_id="O4" value="1.0" spread="1.73"/>
                    <measurement group_id="O5" value="0.9" spread="2.32"/>
                    <measurement group_id="O6" value="1.4" spread="2.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="604"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="328"/>
                    <count group_id="O6" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="1.70"/>
                    <measurement group_id="O2" value="1.0" spread="2.91"/>
                    <measurement group_id="O3" value="1.7" spread="3.09"/>
                    <measurement group_id="O4" value="1.0" spread="1.73"/>
                    <measurement group_id="O5" value="1.0" spread="2.57"/>
                    <measurement group_id="O6" value="1.6" spread="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Indacaterol</title>
          <description>Indacaterol</description>
        </group>
        <group group_id="E2">
          <title>Tiotropium</title>
          <description>Tiotropium</description>
        </group>
        <group group_id="E3">
          <title>Salemeterol/Fluticasone</title>
          <description>Salemeterol/Fluticasone</description>
        </group>
        <group group_id="E4">
          <title>Budesonide/Formoterol</title>
          <description>Budesonide/Formoterol</description>
        </group>
        <group group_id="E5">
          <title>Indacaterol + Tiotropium</title>
          <description>Indacaterol + Tiotropium</description>
        </group>
        <group group_id="E6">
          <title>Salemeterol/Fluticasone(or Budesonide/Formoterol)+Tiotropium</title>
          <description>Salemeterol/Fluticasone(or Budesonide/Formoterol)+Tiotropium</description>
        </group>
        <group group_id="E7">
          <title>Oral Theophylline</title>
          <description>Oral Theophylline</description>
        </group>
        <group group_id="E8">
          <title>Other</title>
          <description>Other</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Unstable angina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Positional vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Infectious pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Spondyloarthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Malignant lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Post herpetic neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Spontaneous pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="632"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceutical</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

